Gujarat Themis Biosyn Ltd Q3 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/myfwhzrpl9zb3w8p43qqwqpe.pdf

Key Takeaways


The Rifa-S Tender Overhang

Patel: "We are not stopping our production because we anticipate that as the tuberculosis tenders open up, the demand is going to be there, quite a significant demand is going to be there... the fact that we are not stopping production is an indicator that we believe this is very realistic."

Capex Program: API Block, R&D Labs & Fermentation

Patel: "We need to be very, very careful in terms of the products that we select, so as to make sure that we have healthy bottom-lines which are much required to sustain this kind of business."

R&D Investment & Margin Impact

Patel: "I believe that one, at least one product would have a significant potential in the very near future because it is something that is expected to change the current therapy, and we'll be one of the first few of the companies to launch this particular product in India and elsewhere too."

Margin Structure & Forward Integration

Patel: "If we are moving into forward integration I don't believe that the margins would be as healthy as they are in fermentation, because the minute you are moving into forward integration there are significant number of companies that are doing the same thing."

Capacity Utilization & Production

Patel: "I would honestly say that it's a case-to-case basis because if we feel that we can produce anything in fermentation just because we do fermentation I think it could be at tall task. It would be incorrect for us to state that we can produce everything under the earth."

Guidance & Commitments

CommitmentSpecificsTimeline
Tender-driven volume recoverySignificant increase in Rifa-S volumes when TB tenders openOver the next two quarters
API block operationalFacility up and running; all INR 40 crores spentJune-July 2023
R&D labs operationalFirst section running; second section runningJune-July 2023; ~November 2023
API block commercializationSome products commercializable 6-9 months post-completion~Jan-April 2024
Fermentation block capacityAdditional capacity available; trial batches beginJune-July FY24
Revenue growth25% to 30% growth, which the API block should help attainNext financial year
Production utilizationRun at 100% capacity vs 75% historicallyCurrent year
API regulatory filingsFilings in regulated markets (if not US, at least some) with orders expectedNext financial year

Key Metrics

MetricQ3 FY23
Revenue₹28.2 cr, 51.4% YoY rise
9M FY23 revenue₹120.8 cr, already surpassed full FY22 revenue
EBITDA₹12.1 cr, 23.6% YoY increase
EBITDA margin43%, down 966 bps YoY
R&D expenditure₹2.44 cr, had a bearing on profit margins
PAT₹9.8 cr, vs ₹7.1 cr in Q3 FY22
Net profit margin34.8%
EPS₹6.75
Revenue growth target for next financial year25% to 30%, API block expected to help attain this
Production capacity utilization plan for FY23100%, up from 75% in the last two years
Capex plan₹200 cr over next 2–3 years
Capex spent so far₹14 cr
CWIP₹13 cr
API block capex₹40 cr out of ₹80 cr Phase 1, all to be spent by July
Average power consumption~3 megawatt peak load, uniformly used
Gross margin over material cost for API block40% to 50%